| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Sterility | 0.2 μm Filtered |
| Target | BAFF |
| Alternative Names | TNFSF13B, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20, TNLG7A, ZTNF4 |
| Clone | tabalumab |
| Source/Isotype | Human IgG4, Kappa |
| Application | Bioactivity-ELISA |
| Description | Tabalumab is a humanized IgG4 monoclonal antibody that targets b-cell activating factor (BAFF/Blys/TNFSF13B) , inhibits its binding to b-cell receptors by neutralizing soluble and membrane-bound BAFF, and inhibits its binding to b-cell receptors, thus, it can regulate the activation, proliferation and antibody production of B cells, and has potential value in the treatment of autoimmune diseases. As a BAFF inhibitor developed by Eli Lilly, its mechanism of action focuses on blocking BAFF-mediated b-cell survival signals, reducing abnormal autoantibody production, and reducing the risk of BAFF-mediated apoptosis, in theory, it could be used to treat diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) . |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Sterility | 0.2 μm Filtered |
| Target | BAFF |
| Alternative Names | TNFSF13B, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20, TNLG7A, ZTNF4 |
| Clone | tabalumab |
| Source/Isotype | Human IgG4, Kappa |
| Application | Bioactivity-ELISA |
| Description | Tabalumab is a humanized IgG4 monoclonal antibody that targets b-cell activating factor (BAFF/Blys/TNFSF13B) , inhibits its binding to b-cell receptors by neutralizing soluble and membrane-bound BAFF, and inhibits its binding to b-cell receptors, thus, it can regulate the activation, proliferation and antibody production of B cells, and has potential value in the treatment of autoimmune diseases. As a BAFF inhibitor developed by Eli Lilly, its mechanism of action focuses on blocking BAFF-mediated b-cell survival signals, reducing abnormal autoantibody production, and reducing the risk of BAFF-mediated apoptosis, in theory, it could be used to treat diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) . |
| Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
